{"id":"W2749746182","doi":"10.1016/s1470-2045(17)30578-8","title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"ca_institutions":"CancerCare Manitoba","funders":"Onyx Pharmaceuticals; Amgen","keywords":"Carfilzomib; Bortezomib; Medicine; Interim analysis; Multiple myeloma; Dexamethasone; Proteasome inhibitor; Tolerability; Internal medicine; Refractory (planetary science); Clinical trial; Oncology; Surgery; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002752159,0.0003106656,0.002408644,0.0003384835,0.0002767042,0.00009776642,0.001443172,0.0002669843,0.0007839966],"category_scores_gemma":[0.003002085,0.0001727098,0.0001383918,0.0002972493,0.000405315,0.0003382291,0.0004141796,0.0005415448,0.00001458362],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00036651,"about_ca_system_score_gemma":0.0008541424,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00424354,"about_ca_topic_score_gemma":0.03634358,"domain_scores_codex":[0.9959409,0.001535458,0.0008072522,0.0006059749,0.0004162975,0.0006940891],"domain_scores_gemma":[0.9954241,0.001209856,0.0006361769,0.002195283,0.0001692113,0.0003653796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9226177,0.008086774,0.005880653,0.00003731708,0.002242309,0.001386143,0.0007441287,0.000006845998,0.007136915,0.000034709,0.0003214163,0.05150512],"study_design_scores_gemma":[0.8935601,0.02472346,0.06643164,0.00004897486,0.001156321,0.0000307837,0.000269325,0.009049005,0.0006584504,0.00003893728,0.003813494,0.000219535],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920183,0.00004826544,0.00001557819,0.001027107,0.0004124186,0.002785695,0.0002571335,0.00003847167,0.003397071],"genre_scores_gemma":[0.9957392,0.0001923372,0.001191483,0.0002813523,0.0005518643,0.000355512,0.0003580068,0.00004002802,0.001290266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06055099,"threshold_uncertainty_score":0.9812406,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2558644524284098,"score_gpt":0.4978180911776169,"score_spread":0.2419536387492071,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}